Dexterra Announces Renewal of Normal Course Issuer Bid
Dexterra Group (TSX: DXT) has received TSX approval to renew its Normal Course Issuer Bid (NCIB) program. The new NCIB will run from May 23, 2025 to May 22, 2026, allowing Dexterra to repurchase up to 3,115,173 common shares, representing 5% of outstanding shares. The company can purchase up to 6,566 shares daily, based on 25% of the six-month ADTV of 26,265 shares.
Under its previous NCIB, Dexterra has purchased 2,086,900 shares at an average price of C$7.1921, totaling C$15,009,121.91. The company believes its shares are undervalued and do not reflect its business value and future prospects. Additionally, Dexterra announced an automatic share purchase plan (ASPP) with a designated broker to facilitate share purchases during blackout periods.
Dexterra Group (TSX: DXT) ha ottenuto l'approvazione della TSX per rinnovare il suo programma di Normal Course Issuer Bid (NCIB). Il nuovo NCIB sarà attivo dal 23 maggio 2025 al 22 maggio 2026, consentendo a Dexterra di riacquistare fino a 3.115.173 azioni ordinarie, pari al 5% delle azioni in circolazione. L'azienda può acquistare fino a 6.566 azioni al giorno, basandosi sul 25% del volume medio giornaliero scambiato (ADTV) degli ultimi sei mesi, pari a 26.265 azioni.
Durante il precedente NCIB, Dexterra ha acquistato 2.086.900 azioni a un prezzo medio di 7,1921 C$, per un totale di 15.009.121,91 C$. L'azienda ritiene che le sue azioni siano sottovalutate e non riflettano il valore del business né le prospettive future. Inoltre, Dexterra ha annunciato un piano automatico di acquisto azionario (ASPP) con un broker designato per facilitare gli acquisti durante i periodi di blackout.
Dexterra Group (TSX: DXT) ha recibido la aprobación de la TSX para renovar su programa Normal Course Issuer Bid (NCIB). El nuevo NCIB estará vigente desde el 23 de mayo de 2025 hasta el 22 de mayo de 2026, permitiendo a Dexterra recomprar hasta 3,115,173 acciones comunes, lo que representa el 5% de las acciones en circulación. La compañía puede comprar hasta 6,566 acciones por día, basado en el 25% del volumen promedio diario negociado (ADTV) de seis meses, que es de 26,265 acciones.
Bajo su NCIB anterior, Dexterra ha comprado 2,086,900 acciones a un precio promedio de 7.1921 C$, totalizando 15,009,121.91 C$. La empresa considera que sus acciones están infravaloradas y no reflejan el valor de su negocio ni sus perspectivas futuras. Además, Dexterra anunció un plan automático de compra de acciones (ASPP) con un corredor designado para facilitar las compras durante los períodos de blackout.
Dexterra Group (TSX: DXT)는 TSX로부터 정상 거래 발행자 매입 프로그램(NCIB) 갱신 승인을 받았습니다. 새로운 NCIB는 2025년 5월 23일부터 2026년 5월 22일까지 진행되며, Dexterra는 최대 3,115,173 보통주를 재매입할 수 있습니다. 이는 발행 주식의 5%에 해당합니다. 회사는 6개월 평균 일일 거래량(ADTV) 26,265주의 25%를 기준으로 하루 최대 6,566주를 매입할 수 있습니다.
이전 NCIB 기간 동안 Dexterra는 평균 가격 C$7.1921에 2,086,900주를 매입했으며, 총액은 C$15,009,121.91입니다. 회사는 자사 주식이 저평가되어 있으며 사업 가치와 미래 전망을 반영하지 못한다고 판단합니다. 또한, Dexterra는 지정 중개인과 함께 자동 주식 매입 계획(ASPP)을 발표하여 블랙아웃 기간 동안 주식 매입을 원활히 할 예정입니다.
Dexterra Group (TSX : DXT) a obtenu l'approbation de la TSX pour renouveler son programme Normal Course Issuer Bid (NCIB). Le nouveau NCIB s'étendra du 23 mai 2025 au 22 mai 2026, permettant à Dexterra de racheter jusqu'à 3 115 173 actions ordinaires, soit 5 % des actions en circulation. La société peut acheter jusqu'à 6 566 actions par jour, sur la base de 25 % du volume quotidien moyen sur six mois (ADTV) de 26 265 actions.
Dans le cadre de son précédent NCIB, Dexterra a acheté 2 086 900 actions à un prix moyen de 7,1921 C$, pour un total de 15 009 121,91 C$. La société estime que ses actions sont sous-évaluées et ne reflètent pas la valeur de son entreprise ni ses perspectives futures. De plus, Dexterra a annoncé un plan d'achat automatique d'actions (ASPP) avec un courtier désigné pour faciliter les achats d'actions pendant les périodes de blackout.
Dexterra Group (TSX: DXT) hat die Genehmigung der TSX erhalten, sein Normal Course Issuer Bid (NCIB)-Programm zu erneuern. Das neue NCIB läuft vom 23. Mai 2025 bis zum 22. Mai 2026 und ermöglicht es Dexterra, bis zu 3.115.173 Stammaktien zurückzukaufen, was 5 % der ausstehenden Aktien entspricht. Das Unternehmen kann täglich bis zu 6.566 Aktien kaufen, basierend auf 25 % des sechsmonatigen durchschnittlichen täglichen Handelsvolumens (ADTV) von 26.265 Aktien.
Im Rahmen des vorherigen NCIB hat Dexterra 2.086.900 Aktien zu einem Durchschnittspreis von 7,1921 C$ erworben, insgesamt 15.009.121,91 C$. Das Unternehmen ist der Ansicht, dass seine Aktien unterbewertet sind und den Unternehmenswert sowie die zukünftigen Aussichten nicht widerspiegeln. Zusätzlich hat Dexterra einen automatischen Aktienkaufplan (ASPP) mit einem benannten Broker angekündigt, um Aktienkäufe während Sperrzeiten zu erleichtern.
- Company believes shares are undervalued, indicating confidence in business value and future prospects
- Implementation of ASPP allows for consistent share repurchases even during blackout periods
- Previous NCIB demonstrated strong buyback execution with over 2 million shares purchased
- Company did not reach maximum allowance under prior NCIB due to daily trading limits
- Daily purchase limit of 6,566 shares may restrict the pace of buyback execution
Toronto, Ontario--(Newsfile Corp. - May 21, 2025) - Dexterra Group Inc. (TSX: DXT) ("Dexterra") is pleased to announce that the Toronto Stock Exchange ("TSX") has approved its notice of intention to renew its normal course issuer bid ("NCIB"). Pursuant to the terms of the NCIB, commencing on May 23, 2025 and expiring on May 22, 2026, Dexterra may purchase its own common shares for cancellation through the facilities of the TSX or alternative Canadian trading systems, in accordance with the applicable requirements, and as otherwise permitted under applicable securities laws. The maximum number of common shares which may be purchased by Dexterra during the NCIB will not exceed 3,115,173 common shares being five percent (
In addition to providing shareholders liquidity, Dexterra believes that the common shares have been trading in a price range which does not adequately reflect their value in relation to Dexterra's business and its future prospects. Dexterra further believes that the purchase of the common shares through the NCIB, at appropriate times, constitutes an attractive investment.
Under its prior NCIB that commenced on May 23, 2024 and terminates on May 22, 2025, Dexterra previously sought and received approval from the TSX to repurchase up to 3,207,361 common shares. During and pursuant to its previously authorized NCIB, to date Dexterra has purchased an aggregate of 2,086,900 common shares through the facilities of the TSX and alternative Canadian trading systems at a weighted-average price of C
Dexterra also announces that it is entering into an automatic share purchase plan (the "ASPP") with a designated broker to allow for the purchase of its common shares under its NCIB at times when Dexterra normally would not be active in the market due to applicable regulatory restrictions or internal trading black-out periods. Before the commencement of any particular internal trading black-out period, Dexterra may, but is not required to, instruct its designated broker to make purchases of the common shares under the NCIB during the ensuing black-out period in accordance with the terms of the ASPP. Such purchases will be determined by the broker in its sole discretion based on parameters established by Dexterra prior to commencement of the applicable black-out period in accordance with the terms of the ASPP and applicable TSX rules. Outside of these black-out periods, common shares will be purchasable by Dexterra at its discretion under its NCIB.
The NCIB and ASPP is effective as of May 23, 2025 and will terminate on the earliest of the date on which: (a) the maximum annual purchase limit under the NCIB has been reached; (b) the NCIB expires; or (c) Dexterra terminates the ASPP in accordance with its terms. The ASPP constitutes an "automatic securities purchase plan" under applicable Canadian securities laws.
About Dexterra
Dexterra employs more than 9,000 people, delivering a range of support services for the creation, management, and operation of infrastructure across Canada and the U.S.
Powered by people, Dexterra brings best-in-class regional expertise to every challenge and delivers innovative solutions, giving clients confidence in their day-to-day operations. Activities include a comprehensive range of integrated facilities management services, industry-leading workforce accommodation solutions, and other support services for diverse clients in the public and private sectors.
For further information, contact:
Denise Achonu, CFO
Head office: Airway Centre, 5925 Airport Rd., Suite 1000
Mississauga, Ontario L4V 1W1
Telephone: (905) 270-1964
You can also visit our website at dexterra.com.
Forward-Looking Information
Certain statements contained in this news release may constitute forward-looking information under applicable securities law. Forward-looking information may relate to Dexterra's future outlook and anticipated events, business, operations, financial performance, financial condition or results and, in some cases, can be identified by terminology such as "continue"; "forecast"; "may"; "will"; "project"; "could"; "should"; "expect"; "plan"; "anticipate"; "believe"; "outlook"; "target"; "intend"; "estimate"; "predict"; "might"; "potential"; "continue"; "foresee"; "ensure" or other similar expressions concerning matters that are not historical facts. In particular, statements regarding Dexterra's future purchases under the NCIB are forward-looking statements. These statements are based on certain factors and assumptions, including expected growth, market recovery, results of operations, performance and business prospects and opportunities regarding Dexterra. While management considers these assumptions to be reasonable based on information currently available to Dexterra, they may prove to be incorrect. Forward-looking information is also subject to certain known and unknown risks, uncertainties and other factors that could cause Dexterra's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking information, including, but not limited to: the ability to retain clients, renew existing contracts and obtain new business; an outbreak of contagious disease that could disrupt its business; the highly competitive nature of the industries in which Dexterra operates; outsourcing of services trends; reliance on suppliers and subcontractors; cost inflation; U.S. tariff impacts; volatility of industry conditions could impact demand for its services; a reduction in the availability of credit could reduce demand for Dexterra's products and services; Dexterra's significant shareholder may substantially influence its direction and operations and its interests may not align with other shareholders; its significant shareholder's
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/252789